FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * Serlin Philip A	2. Date of Event Requiring Statement (MM/DD/YYYY) 3/18/2026	3. Issuer Name and Ticker or Trading Symbol BioLineRx Ltd. [BLRX]
(Last)        (First)        (Middle) BIOLINERX LTD. 2 HAMA'AYAN STREET	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director                          _____ 10% Owner ___X___ Officer (give title below)        _____ Other (specify below) Chief Executive Officer /
(Street) MODII'N  7177871       (City)              (State)              (Zip/Postal Code)	5. If Amendment, Date Original Filed(MM/DD/YYYY)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person
ISRAEL
(Country)

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares, 0.1 NIS per share	5,131,800	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy) (1)(2)	10/10/2017	10/10/2026	Ordinary Shares	55,800 (9)	$0.264	D
Employee Stock Option (Right to Buy) (1)(3)	7/5/2018	7/5/2027	Ordinary Shares	316,200 (9)	$0.284	D
Employee Stock Option (Right to Buy) (1)(4)	12/26/2018	4/16/2028	Ordinary Shares	719,400 (9)	$0.285	D
Employee Stock Option (Right to Buy) (1)(5)	3/25/2020	11/7/2029	Ordinary Shares	1,136,400 (9)	$0.287	D
Employee Stock Option (Right to Buy) (1)(6)	11/17/2021	4/5/2031	Ordinary Shares	3,301,200 (9)	$0.152	D
Employee Stock Option (Right to Buy) (1)(7)	3/15/2023	8/15/2032	Ordinary Shares	4,194,600 (9)	$0.102	D
Employee Stock Option (Right to Buy) (1)(8)	3/21/2024	9/6/2033	Ordinary Shares	4,495,200 (9)	$0.045	D

Explanation of Responses:
(1)	Options granted under the 2003 Amended and Restated Share Incentive Plan.
(2)	The grant date of this grant is October 10, 2016. This option grant is fully vested as of this date.
(3)	The grant date of this grant is July 05 ,2017. This option grant is fully vested as of this date.
(4)	The grant date of this grant is April 16, 2018. This option grant is fully vested as of this date.
(5)	The grant date of this grant is November 07, 2019. This option grant is fully vested as of this date.
(6)	The grant date of this grant is April 05, 2021. This option grant is fully vested as of this date.
(7)	The grant date of this grant is August 15, 2022. This option grant is fully vested as of this date.
(8)	The grant date of this grant is September 06, 2023. As of this date, 3,090,600 options of this grant are vested. The remaining 1,404,600 options will vest in equal 5 quarterly installments, subject to the Reporting Person's continued service to the Issuer as of each vesting date.
(9)	To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the 2003 Amended and Restated Share Incentive Plan must be registered in the name of a trustee.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Serlin Philip A BIOLINERX LTD. 2 HAMA'AYAN STREET MODII'N 7177871 ISRAEL			Chief Executive Officer

Signatures
/s/ Philip Serlin		3/18/2026
**Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
* Form 3: SEC 1473 (03-26).